Sun Pharma ‘bull’ explains the benefits of the potential Organon acquisition

Macquarie believes the transaction appears strategically attractive, based on the complementary nature of the two companies’ portfolios and geographic presence.

Leave a Reply

Your email address will not be published. Required fields are marked *